Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1976 4
1977 1
1978 5
1979 1
1980 1
1983 2
1984 5
1985 4
1986 5
1987 3
1988 2
1993 2
1994 2
1995 1
1996 1
1997 1
1998 2
1999 1
2000 5
2001 3
2002 5
2003 3
2004 4
2005 11
2006 7
2007 5
2008 16
2009 13
2010 10
2011 12
2012 24
2013 21
2014 25
2015 20
2016 30
2017 29
2018 53
2019 54
2020 49
2021 57
2022 74
2023 69
2024 61
2025 46

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

657 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.
Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, Chung HC, Kawakami H, Yabusaki H, Lee J, Saito K, Kawaguchi Y, Kamio T, Kojima A, Sugihara M, Yamaguchi K; DESTINY-Gastric01 Investigators. Shitara K, et al. Among authors: sakai d. N Engl J Med. 2020 Jun 18;382(25):2419-2430. doi: 10.1056/NEJMoa2004413. Epub 2020 May 29. N Engl J Med. 2020. PMID: 32469182 Clinical Trial.
Another milestone, accomplished!
Alini M, Mauck R, Sakai D. Alini M, et al. Among authors: sakai d. JOR Spine. 2022 Jun 28;5(2):e1211. doi: 10.1002/jsp2.1211. eCollection 2022 Jun. JOR Spine. 2022. PMID: 35783911 Free PMC article. No abstract available.
Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA).
Ioka T, Kanai M, Kobayashi S, Sakai D, Eguchi H, Baba H, Seo S, Taketomi A, Takayama T, Yamaue H, Takahashi M, Sho M, Kamei K, Fujimoto J, Toyoda M, Shimizu J, Goto T, Shindo Y, Yoshimura K, Hatano E, Nagano H; Kansai Hepatobiliary Oncology Group (KHBO). Ioka T, et al. Among authors: sakai d. J Hepatobiliary Pancreat Sci. 2023 Jan;30(1):102-110. doi: 10.1002/jhbp.1219. Epub 2022 Aug 9. J Hepatobiliary Pancreat Sci. 2023. PMID: 35900311 Free PMC article. Clinical Trial.
Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial.
Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, Chung HC, Kawakami H, Yabusaki H, Sakamoto Y, Nishina T, Inaki K, Kuwahara Y, Wada N, Suto F, Arita T, Sugihara M, Tsuchihashi Z, Saito K, Kojima A, Yamaguchi K. Shitara K, et al. Among authors: sakai d. Nat Med. 2024 Jul;30(7):1933-1942. doi: 10.1038/s41591-024-02992-x. Epub 2024 May 14. Nat Med. 2024. PMID: 38745009 Free PMC article. Clinical Trial.
Trastuzumab Deruxtecan in Anti-Human Epidermal Growth Factor Receptor 2 Treatment-Naive Patients With Human Epidermal Growth Factor Receptor 2-Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial.
Yamaguchi K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, Chung HC, Kawakami H, Yabusaki H, Lee J, Shimoyama T, Lee KW, Saito K, Kawaguchi Y, Kamio T, Kojima A, Sugihara M, Shitara K. Yamaguchi K, et al. Among authors: sakai d. J Clin Oncol. 2023 Feb 1;41(4):816-825. doi: 10.1200/JCO.22.00575. Epub 2022 Nov 15. J Clin Oncol. 2023. PMID: 36379002 Free PMC article. Clinical Trial.
Trastuzumab Deruxtecan in Advanced Solid Tumors With Human Epidermal Growth Factor Receptor 2 Amplification Identified by Plasma Cell-Free DNA Testing: A Multicenter, Single-Arm, Phase II Basket Trial.
Yagisawa M, Taniguchi H, Satoh T, Kadowaki S, Sunakawa Y, Nishina T, Komatsu Y, Esaki T, Sakai D, Doi A, Kajiwara T, Ono H, Asano M, Hirano N, Odegaard J, Fujii S, Nomura S, Bando H, Sato A, Yoshino T, Nakamura Y. Yagisawa M, et al. Among authors: sakai d. J Clin Oncol. 2024 Nov 10;42(32):3817-3825. doi: 10.1200/JCO.23.02626. Epub 2024 Aug 1. J Clin Oncol. 2024. PMID: 39088783 Free PMC article. Clinical Trial.
Difficult times!
Alini M, Mauck R, Sakai D. Alini M, et al. Among authors: sakai d. JOR Spine. 2020 Jun 23;3(2):e1101. doi: 10.1002/jsp2.1101. eCollection 2020 Jun. JOR Spine. 2020. PMID: 32613169 Free PMC article. No abstract available.
Phase IIb study of pembrolizumab combined with S-1 + oxaliplatin or S-1 + cisplatin as first-line chemotherapy for gastric cancer.
Yamaguchi K, Minashi K, Sakai D, Nishina T, Omuro Y, Tsuda M, Iwagami S, Kawakami H, Esaki T, Sugimoto N, Oshima T, Kato K, Amagai K, Hosaka H, Komine K, Yasui H, Negoro Y, Ishido K, Tsushima T, Han S, Shiratori S, Takami T, Shitara K. Yamaguchi K, et al. Among authors: sakai d. Cancer Sci. 2022 Aug;113(8):2814-2827. doi: 10.1111/cas.15462. Epub 2022 Jul 1. Cancer Sci. 2022. PMID: 35701865 Free PMC article. Clinical Trial.
Advancing spinal research beyond COVID-19.
Sakai D, Leon R, Alini M. Sakai D, et al. JOR Spine. 2023 Mar 27;6(1):e1255. doi: 10.1002/jsp2.1255. eCollection 2023 Mar. JOR Spine. 2023. PMID: 36994460 Free PMC article. No abstract available.
@JORSPine.
Mauck R, Alini M, Sakai D. Mauck R, et al. Among authors: sakai d. JOR Spine. 2021 Sep 29;4(3):e1172. doi: 10.1002/jsp2.1172. eCollection 2021 Sep. JOR Spine. 2021. PMID: 34611594 Free PMC article. No abstract available.
657 results